Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Keywords: COPD Lung function Exacerbations Quality of Life
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 843
Healthy volunteers: no

Brief summary:
To evaluate the efficacy and safety of LAS 34273 compared to placebo in patients with moderate to severe COPD during one year of treatment.

Detailed description:

Arms:
arm 1: Aclidinium bromide 200 μg once-daily by inhalation arm 2: Placebo once-daily via inhalation

Interventions: intervention 1: Aclidinium bromide intervention 2: Placebo
Intervention descriptions: intervention 1: Aclidinium bromide 200 μg once-daily via inhalation via the Eklira Genuair® inhaler: 1 puff in the morning for 52 weeks intervention 2: Placebo once-daily via inhalation: 1 puff in the morning for 52 weeks

Protocol document: